121 related articles for article (PubMed ID: 21704168)
1. Molecular nuclear therapies for thyroid carcinoma.
Verburg FA; Brans B; Mottaghy FM
Methods; 2011 Nov; 55(3):230-7. PubMed ID: 21704168
[TBL] [Abstract][Full Text] [Related]
2. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic advances in the management of progressive thyroid cancer.
Woyach JA; Shah MH
Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279
[TBL] [Abstract][Full Text] [Related]
4. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
5. Correlation of clinicopathological features and expression of molecular markers with prognosis after ¹³¹I treatment of differentiated thyroid carcinoma.
Qin C; Cau W; Zhang Y; Mghanga FP; Lan X; Gao Z; An R
Clin Nucl Med; 2012 Mar; 37(3):e40-6. PubMed ID: 22310269
[TBL] [Abstract][Full Text] [Related]
6. The sodium-iodine symporter and the proton-pump inhibitors in - related to the side effects of- the treatment of thyroid cancer with iodine-131.
Sfakianakis G; Sfakianaki E
Hell J Nucl Med; 2007; 10(1):2-5. PubMed ID: 17450241
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and therapy of thyroid cancer in childhood and adolescence.
Bucsky P; Parlowsky T
Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 4():70-3. PubMed ID: 9439921
[TBL] [Abstract][Full Text] [Related]
8. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor.
Zarnegar R; Brunaud L; Kanauchi H; Wong M; Fung M; Ginzinger D; Duh QY; Clark OH
Surgery; 2002 Dec; 132(6):984-90; discussion 990. PubMed ID: 12490845
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer.
Padma S; Sundaram PS
J Cancer Res Ther; 2016; 12(3):1109-1113. PubMed ID: 28054519
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
11. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous medullary carcinoma and differentiated thyroid cancer. Case report.
Costanzo M; Marziani A; Papa V; Arcerito MC; Cannizzaro MA
Ann Ital Chir; 2010; 81(5):357-60. PubMed ID: 21294389
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in radioiodine refractory thyroid cancer.
Pacini F; Brilli L; Marchisotta S
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
Chow SM; Yau S; Lee SH; Leung WM; Law SC
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
16. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
17. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]